Myla R.

Reizen

Position: Partner
Office: Miami

Myla Reizen is a partner in the Corporate Practice Group and a member of the firm’s Healthcare Industry Team, where she focuses her practice on government and internal investigations, healthcare regulatory matters, and compliance.

Myla has extensive experience representing international and national organizations and individual clients from every sector of the complex, competitive, and highly regulated healthcare industry. She also draws on her firsthand in-house experience to provide sophisticated, practical advice to a wide array of healthcare providers.

Among other clients, Myla advises public and private health systems, hospitals, academic medical centers, clinical laboratories, home-health agencies, skilled-nursing and other post-acute-care facilities, hospices, physician groups, behavioral-health providers and facilities, durable medical equipment companies, and more.

In Myla’s comprehensive healthcare practice, she advises providers on enforcement and qui tam matters ranging from traditional issues — such as medical necessity; physician arrangements; research and clinical studies; and False Claims Act, Anti-Kickback Statute, Stark Law, and Eliminating Kickbacks in Recovery Act (EKRA) matters — to emerging challenges involving health equity, delivery of healthcare in rural communities, telehealth and telemedicine, drug diversion strategies, and more. She regularly represents clients in internal and government investigations and proceedings before state and federal regulatory and law enforcement agencies, such as the US Department of Justice; this includes analyzing and preparing numerous self-disclosures under a variety of protocols.

Myla has extensive experience developing, assessing, implementing, and managing compliance programs and has negotiated and implemented numerous corporate integrity agreements. In addition to her work on federal issues, she counsels clients across the country on state regulatory and enforcement matters, including reimbursement, licensure, fraud and abuse, and the impact of innovative and novel state healthcare programs. During the COVID-19 pandemic, Myla offered extensive guidance to providers that were significantly impacted by the public health emergency, including the nursing home and long-term care communities.

A recognized legal and industry thought leader, she has written numerous articles on a broad range of healthcare-related topics, such as recent US Supreme Court rulings and other federal appellate decisions, recent changes to the Anti-Kickback Statute safe harbors, the future of EKRA, advancements in health equity the effectiveness of compliance programs, drug diversion compliance, the landscape of self-disclosures, and responding to COVID-era and post-COVID laws and regulations. Myla helps organize, and regularly speaks at, legal and healthcare industry conferences and has been quoted in numerous articles appearing in publications such as Laboratory Economics, McKnight’s, and Report on Medicare Compliance. She is active in a statewide organization focused on healthcare compliance and privacy/security trends, where she regulatory speaks on recent enforcement and compliance settlements and trends.